EIT Health will invest up to €2 million in two start-ups that offer the most effective and disruptive solutions to address either Women’s Health or Digital Therapeutics.Applications for the Wild Card programme are open until 9th February 2020.
19 December, 2019
Somerset, N.J. & Birmingham, Ala.– December 10, 2019 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has completed clinical production of Bridge Therapeutics Inc.’s (Bridge) opioid addiction development therapeutic product, BT-219, and executed an Exclusive Licensing Agreement to use Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology. Bridge currently intends to seek approval from the U.S. FDA for BT-219 under the “505(b)(2)” regulatory submission pathway as well as a possible future single entity buprenorphine product.
17 December, 2019
A team of molecular and structural biologists from Nanyang Technological University, Singapore (NTU Singapore) have found a potential new route to disabling respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) after elucidating the structure of one of its key components.
09 December, 2019